M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:M12 - DE000A0STSQ8 - Common Stock
18.54 EUR
-0.06 (-0.32%)
Taking everything into account, M12 scores 6 out of 10 in our fundamental rating. M12 was compared to 32 industry peers in the Health Care Providers & Services industry. Both the health and profitability get an excellent rating, making M12 a very profitable company, without any liquidiy or solvency issues. M12 has a correct valuation and a medium growth rate. These ratings would make M12 suitable for quality investing!
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
M12 had a positive operating cash flow in the past year.
In the past 5 years M12 has always been profitable.
M12 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
M12 has a better Return On Assets (8.73%) than 96.88% of its industry peers.
M12's Return On Equity of 15.03% is fine compared to the rest of the industry. M12 outperforms 78.13% of its industry peers.
M12's Return On Invested Capital of 13.44% is amongst the best of the industry. M12 outperforms 90.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 7.02%.
The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROIC | 13.44% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
1.3 Margins
Looking at the Profit Margin, with a value of 5.00%, M12 belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
M12's Profit Margin has declined in the last couple of years.
M12 has a Operating Margin of 8.52%. This is amongst the best in the industry. M12 outperforms 81.25% of its industry peers.
M12's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 19.29%, M12 perfoms like the industry average, outperforming 53.13% of the companies in the same industry.
M12's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% |
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M12 is creating value.
The number of shares outstanding for M12 has been reduced compared to 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
The debt/assets ratio for M12 is higher compared to a year ago.
2.2 Solvency
M12 has an Altman-Z score of 5.78. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
M12 has a Altman-Z score of 5.78. This is amongst the best in the industry. M12 outperforms 96.88% of its industry peers.
M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
M12's Debt to FCF ratio of 0.70 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
M12's Debt to Equity ratio of 0.05 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Altman-Z | 5.78 |
ROIC/WACC1.86
WACC7.21%
2.3 Liquidity
M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
M12 has a Current ratio of 2.06. This is amongst the best in the industry. M12 outperforms 93.75% of its industry peers.
A Quick Ratio of 1.35 indicates that M12 should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.35, M12 belongs to the best of the industry, outperforming 84.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 10.36% over the past year.
The Earnings Per Share has been growing slightly by 7.97% on average over the past years.
M12 shows a small growth in Revenue. In the last year, the Revenue has grown by 6.52%.
The Revenue has been growing by 34.44% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
3.2 Future
M12 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.18% yearly.
The Revenue is expected to grow by 8.24% on average over the next years. This is quite good.
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 19.72, M12 is valued on the expensive side.
M12's Price/Earnings is on the same level as the industry average.
M12's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.19.
A Price/Forward Earnings ratio of 15.98 indicates a correct valuation of M12.
The rest of the industry has a similar Price/Forward Earnings ratio as M12.
M12 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.92, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.72 | ||
| Fwd PE | 15.98 |
4.2 Price Multiples
M12's Enterprise Value to EBITDA is on the same level as the industry average.
M12's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.64 | ||
| EV/EBITDA | 9.16 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of M12 may justify a higher PE ratio.
M12's earnings are expected to grow with 19.18% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.8
PEG (5Y)2.48
EPS Next 2Y14.78%
EPS Next 3Y19.18%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 2.69%.
M12's Dividend Yield is rather good when compared to the industry average which is at 1.57. M12 pays more dividend than 87.50% of the companies in the same industry.
M12's Dividend Yield is a higher than the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.69% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
DPN/A
EPS Next 2Y14.78%
EPS Next 3Y19.18%
FRA:M12 (1/9/2026, 7:00:00 PM)
18.54
-0.06 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners0.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap364.13M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85
Price Target27.03 (45.79%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.69% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.72 | ||
| Fwd PE | 15.98 | ||
| P/S | 1.03 | ||
| P/FCF | 13.64 | ||
| P/OCF | 13.47 | ||
| P/B | 3.09 | ||
| P/tB | 13.26 | ||
| EV/EBITDA | 9.16 |
EPS(TTM)0.94
EY5.07%
EPS(NY)1.16
Fwd EY6.26%
FCF(TTM)1.36
FCFY7.33%
OCF(TTM)1.38
OCFY7.43%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)3.8
PEG (5Y)2.48
Graham Number11.27
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.73% | ||
| ROE | 15.03% | ||
| ROCE | 19.39% | ||
| ROIC | 13.44% | ||
| ROICexc | 18.99% | ||
| ROICexgc | 105.66% | ||
| OM | 8.52% | ||
| PM (TTM) | 5% | ||
| GM | 19.29% | ||
| FCFM | 7.52% |
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.7 | ||
| Debt/EBITDA | 0.17 | ||
| Cap/Depr | 6.62% | ||
| Cap/Sales | 0.1% | ||
| Interest Coverage | 21.13 | ||
| Cash Conversion | 76.34% | ||
| Profit Quality | 150.51% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 5.78 |
F-Score9
WACC7.21%
ROIC/WACC1.86
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y5.19%
EPS Next 2Y14.78%
EPS Next 3Y19.18%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year6.09%
Revenue Next 2Y6.66%
Revenue Next 3Y6.53%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year30.73%
EBIT Next 3Y27.49%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A
M1 KLINIKEN AG / M12.DE FAQ
Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?
ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.
What is the valuation status for M12 stock?
ChartMill assigns a valuation rating of 4 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.
How profitable is M1 KLINIKEN AG (M12.DE) stock?
M1 KLINIKEN AG (M12.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for M12 stock?
The Price/Earnings (PE) ratio for M1 KLINIKEN AG (M12.DE) is 19.72 and the Price/Book (PB) ratio is 3.09.
What is the financial health of M1 KLINIKEN AG (M12.DE) stock?
The financial health rating of M1 KLINIKEN AG (M12.DE) is 8 / 10.